2022 Fiscal Year Final Research Report
Production of catalytic antibody for Pictet-Spengler reaction and its application to medicinal plant breeding
Project/Area Number |
20K07101
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 47050:Environmental and natural pharmaceutical resources-related
|
Research Institution | Kyushu University |
Principal Investigator |
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | ストリクトシジン / モノクローナル抗体 / ELISA |
Outline of Final Research Achievements |
Strictosidine (SS) is a common precursor to all terpenoid indole alkaloids (TIAs). In this study, we aimed to produce catalytic antibodies that catalyze the reaction between secologanin and tryptamine to form SS, and to establish an efficient screening method for an antibody with catalytic activity. An anti-SS monoclonal antibody (SS-mAb) is essential for the establishment of this system. Therefore, we first cloned SS synthase (SSS) to prepare SS antigen used to produce SS-mAb. However, due to the low stability of SS, we were unable to produce SS-mAb. Also, in the production of catalytic antibodies, a phenomenon was observed in which the stability of the transition state analog of the immunogen seemed to be a problem, and target catalytic antibodies could not be obtained as well. Catalytic antibodies for SS can be used as a tool for efficient production of TIAs, which are produced in low amounts in plants. Therefore, we will continue to work toward the completion of this project.
|
Free Research Field |
薬用植物育種学
|
Academic Significance and Societal Importance of the Research Achievements |
近年、天然由来化合物をリード化合物とする抗悪性腫瘍薬の価格が高騰する現状にある。SSの生合成を触媒する抗体の薬用植物育種における応用は、下流の希少TIAsの生合成効率を高める可能性がある。そのため、本研究の遂行は微量天然由来化合物であるが故に価格が高騰する抗悪性腫瘍薬の薬価の低下をもたらすことが期待される。 当該研究では、未だSS-mAbや触媒抗体の作製には成功していないもののSS-mAbが得られる可能性が示唆された。SS-mAbも触媒抗体と共にTIAsの生合成を促進させる可能性を秘めており、希少な天然物由来化合物の効率的な量産へ繋がる可能性もあることから、本研究成果の社会的意義は大きい。
|